Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

On May 19, Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese biopharmaceutical firm 3SBio Inc.

In addition, Valneva and Pfizer updated the terms of their collaboration and license agreement which they announced on April 30, 2020 1. Valneva will now fund 40% of the remaining shared ...

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental Covid-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

Written by Zacks Equity Research for Zacks -> Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707.